Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79537 | 1.00 | CASP1 (0.54) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL17261861 | 0.92 | CTSK (0.52) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL12046896 | 0.91 | CASP1 (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL626800 | 0.90 | CASP3 (0.49) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL4422741 | 0.90 | CASP3 (0.49) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL10074125 | 0.90 | CASP3 (0.49) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL87319 | 0.89 | SYK (0.57) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL17731584 | 0.88 | CASP1 (0.54) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL2775895 | 0.88 | PPARA (0.57) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL478289 | 0.88 | PPARA (0.57) | CASP1SYKCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8071618-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071618-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-06 | — | — | US | disclosed |
| US-7923433-B2 | Activity-based probes and methods of their preparation and use | ACTIVX BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923433-B2 | Activity-based probes and methods of their preparation and use | ACTIVX BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003106460-A1 | NOVEL INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003104231-A1 | NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-0946502-B1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6316415-B1 | INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
| EP-0946502-A1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998016505-A1 | SULFONAMIDE INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5710153-A | INTERLEUKIN CONVERTING ENZYME INHIBITORS | ONO PHRAMACEUTICAL CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
| EP-0761680-A2 | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137359-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, CASP5 | CASP1 2/4885SYK 3348/4885CTSK 696/4885 |
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1R1 | CASP1 11/4885SYK 1651/4885CTSK 467/4885 |
| US-20030236296-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1R1, IL1B, IL1RN | CASP1 65/4885SYK 3739/4885CTSK 943/4885 |
| US-20090281128-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | CASP1 1/4885SYK 1687/4885CTSK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.